NRXP: NRx Pharmaceuticals, Inc. Stock

by  •  • Comments Off on NRXP: NRx Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 33.35
Enterprise Value ($M) 37.92
Book Value ($M) -15.07
Book Value / Share -1.12
Price / Book -2.84
NCAV ($M) -15.51
NCAV / Share -1.48
Price / NCAV -2.15

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -1.38
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.18
Current Ratio 0.36

Balance Sheet (mrq) ($M)
Current Assets 3.35
Assets 3.79
Liabilities 18.86
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -27.59
Net Income -30.15
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -21.66
Cash from Investing -0.00
Cash from Financing 6.20

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2023 ☐ TRANSITION REPORT PURSU
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2023 ☐ TRANSITION REP
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2023 ☐ TRANSITION REPORT P
2023-05-26 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2022 ¨ TRA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-15 35,566 168,341 21.13
2024-05-14 67,656 246,205 27.48
2024-05-13 47,474 23,246 204.22
2024-05-10 74,228 62,203 119.33

(click for more detail)

Similar Companies
NLSP – NLS Pharmaceutics Ltd. NRBO – NeuroBo Pharmaceuticals, Inc.
NRSN – NeuroSense Therapeutics Ltd. NTBL – Notable Labs, Ltd.
NVCT – Nuvectis Pharma, Inc.


Financial data and stock pages provided by
Fintel.io